key: cord-0837497-ds4n8dbw authors: Onsun, Nahide; Güneş, Begüm; Yabacı, Ayşegül title: Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID‐19 pandemic: The real‐world experience of a single center date: 2020-12-11 journal: Dermatol Ther DOI: 10.1111/dth.14623 sha: e8f4ec9868b671a57d323f0e0325fae250d87eef doc_id: 837497 cord_uid: ds4n8dbw There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long‐term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR‐TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID‐19 pandemic, were also investigated. The data for BMI and other patient characteristics are shown in Table 1 . The mean duration of treatment was 28.39 ± 28.65 months (range: 1-156 months), and the median and maximum duration of treatment was 17 months and 13 years, respectively. Thirty-six patients ( Etanercept treatment was continued for less than 5 years in 87% (n = 215) of the patients. While 11% (n = 27) of the patients continued etanercept treatment for a period of 5-10 years, only 2% (n = 5) continued the treatment for more than 10 years. Reasons for discontinuation were ineffectiveness (n = 101 patients; 41%), patient's choice (n = 55; 22%) and pregnancy planning (n = 4; 1.6%). Twenty-six (10.5%) patients discontinued treatment because of adverse effects. The most common side effect was an increase in liver enzyme levels (n = 17; 6.9%). However, as these patients received additional isoniazid (isonicotinic acid hydrazide, INH) for prophylaxis against tuberculosis, this effect may not have been directly attributable to etanercept. During this period, two patients developed pulmonary tuberculosis (reactivation of latent tuberculosis) despite INH prophylaxis. Other serious adverse events occurring during etanercept treatment were renal cell cancer in one male patient and autoimmune nephritis in one female patient ( Polymenorrhea was observed in an adolescent girl in our series, and was also reported in post-marketing data from the UK. 14 F I G U R E 1 Short-term efficacy of etanercept. PASI, Psoriasis Area and Severity Index The overall etanercept survival rates were 63%, 41%, 28%, 26%, 13%, 12%, 7%, 2%, and 2% after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 13 years, respectively ( Figure 6 ). Our survival rates were lower than those of previous randomized clinical trials. In a multicenter observational study, Esposito et al reported that etanercept had longer survival than adalimumab and infliximab. 15 We could not make such a comparison because this was not a comparative study. 16 In the present study, adherence was higher in male than female patients, and male sex was a positive predictor of adherence. The presence of arthritis and use of etanercept as a first-line biologic agent were also positive predictors of retention rate. Also, Frazier-Mironer et al reported that etanercept had a better retention rate than adalimumab and infliximab as first-line biotherapy. 17 In cases with an insufficient treatment response, we found that adding a Etanercept: an overview A randomized trial of etanercept as monotherapy for psoriasis A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction Efficacy of bioloigcs in the treatment of moderate severe psoriasis: a network meta-analysis of randomized controlled trials Etanercept fort the tratment of psoriasis Etanercept: efficacy and safety Etanercept: efficacy and safety Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Comparison of long-term drug survival and safety of biologics agents in patients with psoriasis vulgaris Drug survival rates and reasons for drug discontinuation in psoriasis Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis Long-term efficacy of etanercept for psoriasis in daily practice Results of three approaches on long-term efficacy of etanercept for psoriasis in daily practice Drug: Etanercept. Medicines Control Agency Adverse Drug Reactions Online Information Tracking Survival rate of antitumour necrosis factor-a treatments for psoriasis in routine dermatological practice: a multicentre observational study Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice Long-term efficacy of etanercept for plaque-type psoriasis and estimated cost in daily clinical practice The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study Covid-19 in immune-mediated inflammatory diseases-case series from New York Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis COVID-19 in patients with rheumatological diseases treated with anti-TNF How to cite this article: Onsun N, Güneş B, Yabacı A. Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real